Abstract
Peroxisome Proliferator Activated Receptors (PPARs) are a family of three related nuclear receptors first cloned in 1990. Their involvement in glucidic and lipidic homeostasis quickly made them an attractive target for the treatment of metabolic syndrome, the most prevalent mortality factor in developed countries. They therefore attracted much synthetical efforts, more particularly PPARγ. Supported by a large number of crystallographic studies, data derived from these compounds lead to a fairly clear view of the agonist binding mode into the Ligand Binding Domain (LBD). Nearly all the compounds conform to a three-module structure, with a binder group involved in a series of hydrogen bonds in front of the ligand-dependent Activation Function (AF2), a linker mostly arranged around a phenoxyethyl and an effector end occupying the large cavity of the binding site. Following the marketing of the glitazones and the observation of the hepatotoxicity of troglitazone, variations in the binder led to the glitazars, and then pharmacomodulations have been undertaken on the two other modules, leading to a large family of highly related chemical structures. Some compounds, while still adhering to the three-module structure, diverge from the mainstream, such as the phthalates. Curiously, these plasticizers were known to elicit biological effects that led to the discovery of PPARs but were not actively studied as PPARs agonists. As the biological effects of PPARs became clearer, new compounds were also found to exert at least a part of their actions by the activation of PPARγ.
Keywords: PPARγ, agonist, binding mode, crystallography, docking
Current Medicinal Chemistry
Title: Structural Insight into PPARγ Ligands Binding
Volume: 16 Issue: 14
Author(s): A. Farce, N. Renault and P. Chavatte
Affiliation:
Keywords: PPARγ, agonist, binding mode, crystallography, docking
Abstract: Peroxisome Proliferator Activated Receptors (PPARs) are a family of three related nuclear receptors first cloned in 1990. Their involvement in glucidic and lipidic homeostasis quickly made them an attractive target for the treatment of metabolic syndrome, the most prevalent mortality factor in developed countries. They therefore attracted much synthetical efforts, more particularly PPARγ. Supported by a large number of crystallographic studies, data derived from these compounds lead to a fairly clear view of the agonist binding mode into the Ligand Binding Domain (LBD). Nearly all the compounds conform to a three-module structure, with a binder group involved in a series of hydrogen bonds in front of the ligand-dependent Activation Function (AF2), a linker mostly arranged around a phenoxyethyl and an effector end occupying the large cavity of the binding site. Following the marketing of the glitazones and the observation of the hepatotoxicity of troglitazone, variations in the binder led to the glitazars, and then pharmacomodulations have been undertaken on the two other modules, leading to a large family of highly related chemical structures. Some compounds, while still adhering to the three-module structure, diverge from the mainstream, such as the phthalates. Curiously, these plasticizers were known to elicit biological effects that led to the discovery of PPARs but were not actively studied as PPARs agonists. As the biological effects of PPARs became clearer, new compounds were also found to exert at least a part of their actions by the activation of PPARγ.
Export Options
About this article
Cite this article as:
Farce A., Renault N. and Chavatte P., Structural Insight into PPARγ Ligands Binding, Current Medicinal Chemistry 2009; 16 (14) . https://dx.doi.org/10.2174/092986709788186165
DOI https://dx.doi.org/10.2174/092986709788186165 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry Microvascular Alterations in Hypertension and Vascular Aging
Current Hypertension Reviews History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Flavonoid Rich Fraction of Dioscorea bulbifera Linn. (Yam) Enhances Mitochondrial Enzymes and Antioxidant Status, Thereby Protects Heart from Isoproterenol Induced Myocardial Infarction
Current Pharmaceutical Biotechnology Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Epidemiology of Gout: Perspectives from the Past
Current Rheumatology Reviews The Prevalence of Dyslipidemia and Other Cardiovascular Risk Factors in Youth with Diabetes
Current Pediatric Reviews Post-translational Modifications of Proteins: Biomarkers and Therapeutic Targets for Diabetes Related Complications
Current Proteomics Are the Pleiotropic Effects of Telmisartan Clinically Relevant?
Current Pharmaceutical Design The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Analyzing Phytochemicals as Inhibitors of Diabetes Mellitus 2 Causing Proteins based on Computer-Aided Drug Discovery Protocols
The Natural Products Journal Fatty Acids and Obesity
Current Pharmaceutical Design Radiation Dose Reduction in Cardiac CT Angiography by Applying a Low Tube Voltage: A Comparison Among 120, 100 and 80 kVp Protocols
Current Medical Imaging The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews